HQL Tekla Life Sciences Investors
Financial Services$17.19-0.12%ClosedMarket Cap: $522.7M
As of 2026-05-25
Valuation
P/E (TTM)
2.90
PEG
0.01
P/B
0.97
P/S
17.52
EV/EBITDA
6.11
DCF Value
$88.08
FCF Yield
-0.4%
Div Yield
11.9%
Margins & Returns
Gross Margin
30.8%
Operating Margin
286.9%
Net Margin
286.9%
ROE
18.8%
ROA
16.6%
ROIC
16.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $11.6M | 79.0% | $132.8M | $132.8M | $— | $0.42 |
| FY null | $86.4M | 100.0% | $85.6M | $85.6M | $— | $1.82 |
| Q2 null | $18.2M | 0.0% | $-47.2M | $-47.2M | $— | $0.47 |
| Q4 null | $1.9M | 100.0% | $-1.3M | $35.0M | $— | $0.49 |
| FY null | $86.7M | 100.0% | $85.3M | $85.3M | $— | $1.66 |
| Q2 null | $2.1M | 100.0% | $-653.3K | $50.3M | $— | $0.39 |
| Q4 null | $29.6M | 91.2% | $-11.4M | $-11.5M | $— | $0.32 |
| FY null | $39.4M | 46.4% | $-5.2M | $22.4M | $— | $1.28 |
| Q2 null | $1.9M | 100.0% | $-940.7K | $33.8M | $— | $0.33 |
| Q4 null | $21.7M | 87.8% | $-28.3M | $-28.3M | $— | $0.31 |
| FY null | $31.9M | 82.6% | $-104.6M | $-104.6M | $— | $1.47 |
| Q2 null | $10.2M | 71.4% | $-76.3M | $-76.3M | $— | $0.39 |